Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial

Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial

Abstract Background The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established. We aimed to compare the efficacy of irinotecan plus S-1 with S...

Full description

Bibliographic Details
Main Authors: Jing Huang, Binghe Xu, Ying Liu, Junxing Huang, Ping Lu, Yi Ba, Lin Wu, Yuxian Bai, Shu Zhang, Jifeng Feng, Ying Cheng, Jie Li, Lu Wen, Xianglin Yuan, Changwu Ma, Chunhong Hu, Qingxia Fan, Xi Wang
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:Cancer Communications
Subjects:
Esophageal squamous cell carcinoma
Recurrent
Metastasis
Multicenter, open-label, randomized trial
Irinotecan
S-1
Online Access:http://link.springer.com/article/10.1186/s40880-019-0359-7

Internet

http://link.springer.com/article/10.1186/s40880-019-0359-7

Similar Items